|Bid||3.1000 x 900|
|Ask||3.1200 x 1100|
|Day's Range||2.9100 - 3.1850|
|52 Week Range||2.2600 - 7.4800|
|Beta (3Y Monthly)||3.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.42|
GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human.
Biotechnology company Applied Genetic Technologies Corp (NASDAQ: AGTC ) presented interim six-month data Thursday for the Phase 1/2 XLRP program in X-linked retinitis pigmentosa, turning BMO Capital ...
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -13.73% and -42.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Company announces promising topline six-month dose escalation data from its ongoing Phase 1/2 clinical trials for X-linked retinitis pigmentosa (XLRP) Preliminary three-month.
NEW YORK, NY / ACCESSWIRE / September 26, 2019 / Applied Genetic Technologies Corp. (NASDAQ: AGTC ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on September ...
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 25, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 18, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
The big shareholder groups in Applied Genetic Technologies Corporation (NASDAQ:AGTC) have power over the company...
The Italian Achromatopsia Association (IAA) today announced that it is organizing a trip to Pingelap, a remote Micronesian atoll in the South Pacific, also known as the “Island of the Color Blind.” While the incidence of achromatopsia, a rare inherited retinal disease (IRD), in the general population is 1 in every 30,000 individuals, the condition is found in between 10 and 30 percent of Pingelap’s population. The trip was made possible in part by a number of sponsors, including Applied Genetic Technologies Corporation (AGTC), a biotechnology company that is committed to developing transformational genetic therapies for patients suffering from rare diseases, including achromatopsia.
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 07, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has completed enrollment of the third group in the dose escalation portion of its Phase 1/2 clinical trial evaluating the safety and efficacy of subretinal injection of (rAAV2tYF-PR1.7-hCNGA3) for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene. “This achievement is another demonstration of our continued progress in the clinical development of our three product candidates for the treatment of X-linked retinitis pigmentosa and achromatopsia due to mutations in the CNGA3 or CNGB3 gene,” said Sue Washer, president and CEO of AGTC.
Sue Washer has been the CEO of Applied Genetic Technologies Corporation (NASDAQ:AGTC) since 2002. This analysis aims...
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.